-
Fuan Pharmaceutical Escitalopram Oxalate Tablets Entered the Administrative Approval Stage
Time of Update: 2021-03-21
Source: Minet database Medical News, March 15 Recently, Fuan Pharmaceutical entered the administrative examination and approval stage with the imitation of escitalopram oxalate tablets reported for production in Category 4, and it is expected to be approved for production in the near future.
-
Three major products of CSPC have been reviewed successively
Time of Update: 2021-03-21
Medical News, March 15th, March 11-12, NMPA official website shows that CSPC’s nintedanib ethanesulfonate soft capsules and entecavir tablets have been approved for production and deemed to have been reviewed.
-
CSPC's latest announcement is 370 million yuan to win two major varieties
Time of Update: 2021-03-21
According to the agreement, CSPC Shanghai will obtain the exclusive rights of BPI-7711 capsules to carry out commercialization activities of BPI-7711 capsules in the People’s Republic of China (including Hong Kong Special Administrative Region and Macau Special Administrative Region, but excluding Taiwan) and own BPI -1178 Capsules (CDK4/6 inhibitor) commercialization authorization priority negotiation right.
-
The review period of aducanumab, β protein antibody aducanumab, was extended by the FDA for 3 months
Time of Update: 2021-03-12
Based on clinical data from patients with mild cognitive impairment caused by AD and mild AD, aducanumab has the potential to affect the pathophysiology of in-house diseases, slow cognitive and functional decline, and facilitate the patient's ability to carry out daily activities, including managing personal finances, doing household chores such as cleaning, shopping and washing clothes, and traveling independently.
-
Baiotai: Beva Pearl single anti-injection drug market license application was accepted by the FDA
Time of Update: 2021-03-12
On January 27th, Baotai announced that it had submitted to the FDA in the fourth quarter of 2020 an application for the listing of biological products for BAT1706 (Beva Pearl Monoantigen) injections (BLA), and had recently received a notification from the FDA.
-
Well-known pharmaceutical companies have abolished their sales teams
Time of Update: 2021-03-12
Mharma representatives how to deal with the professional test of the above-mentioned people to SaibaiLan said that the reason why more and more pharmaceutical companies began to choose to give varieties to agents to do, mainly because a team of agents can operate multiple varieties at the same time, can accept the situation of profit compression, compared to the enterprise self-built sales team, the cost is relatively small.
-
The treatment of BPDCN by ELZONRIS in Manarini has been approved by the European Commission
Time of Update: 2021-03-12
ELZONRIS ® approved by the U.S. Food and Drug Administration (FDA) in 2018 and is currently available for treatment in adult and pediatric BPDCN patients 2 years of age or older.
-
Hescoe obtains Drug Registration Certificate for Grelo tablets
Time of Update: 2021-03-12
On January 31, Hesco announced that Its wholly-owned subsidiary, Sichuan Haisco Pharmaceutical Co., Ltd., had recently received the "Drug Registration Certificate" issued by the State Drug Administration.
January 2021, Hesco Pharmaceuticals (Meishan) Co., Ltd. was officially approved for production and obtained the Drug Registration Certificate.
-
Conquer the cancer gene! Amjin KRAS inhibitors can control NSCLC progression by 80.6%.
Time of Update: 2021-03-12
On January 28th, global biotech giant Amgen announced the clinical results of phase 2 of its high-profile KRAS G12C inhibitor Sotorasib (AMG 510) for patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation, showing a disease control rate (DCR) of 80.6% and an objective mitigation rate (ORR) of 37.1%!
-
The company's net profit rose by up to 7000 percent! Medical devices are high-gloss and chinese medicine polarized
Time of Update: 2021-03-12
Chemical Pharmaceutical Company's earnings forecast data source: Choice data, Shenwan industry sub-index growth of the largest enterprises are Dongcheng Pharmaceuticals, the expected net profit range of 360 million to 468 million yuan, the expected increase of 132.69 percent to 202.49 percent.
-
FDA approves Vertex clinical test stem cell-derived fully differentiated islet cell therapy
Time of Update: 2021-03-12
Vertex plans to launch a phase 1/2 single-arm, open-label clinical trial in the first half of 2021, using VX-880 to treat patients with type 1 diabetes (T1D) with impaired and severe hypoglycemia.
-
Turning Point/Redding repotrectinib Total remission rate of lung cancer treatment is 93%
Time of Update: 2021-03-12
A total of 15 patients were included in phase 2 of the study, and preliminary efficacy analysis showed that the objective remission rate (ORR) confirmed by the doctor's assessment was 93% (95% CI:68-100); The updated data confirm our belief that repotrectinib has the potential to be the best treatment for patients with ros1-positive TKI advanced non-small cell lung cancer," said Dr. Mohammad Hirmand, Chief Medical Officer, Turing Point Therapeutics.
-
GSK terminates LAG-3 single anti-ulcerative enteritis Phase II study
Time of Update: 2021-03-12
On January 22, Immutep announced that its partner GSK had terminated THE LAG-3 single anti-GSK2831781 (IMP731) Phase II clinical research project for active ulcerative enteritis.
GSK's termination of GSK2831781's ulcerative enteritis Phase II project will not affect Immutep's plans for the development of three other products.
-
The patent is not expiring Pfizer's $6 billion star drug price slash!
Time of Update: 2021-03-12
There is no doubt that in the face of huge market prospects, CDK4/6 has become a hot target for major companies in recent years, according to pharmaceutical data, the FDA has approved a total of three CDK4/6 antidote drugs for breast cancer treatment, namely Pfizer's Ibersili, Novarma's Rebosini, Lilly's Abemaciclib.
-
AbbVie JAK1 inhibitor listing applications are to be included in the priority review
Time of Update: 2021-03-12
Transfer from | According to the latest announcement by the Drug Review Center (CDE) of the State Drug Administration of China, two listing applications for AbbVie's JAK inhibitor Upadacitinib are to be included in the priority review, with the proposed development of adaptive disorders for adults with systemic treatment and severe specialty dermatitis patients in adults aged 12 and over.
-
The innovative anemia therapy of Baishi Meishi Guibao is to be included in the priority review
Time of Update: 2021-03-12
Transfer from | Two applications for injection at Celgene, a subsidiary of BMS, have been included in the proposed priority review list for the treatment of adult β-Thalassemia patients who need regular infusions of red blood cells (RBCs), according to the latest announcement from the Drug Review Center (CDE) of the State Drug Administration of China.
-
New drug for multiple sclerosis! Novart Kesimpta EU is about to be approved
Time of Update: 2021-03-12
Kesimpta is a new targeted B-cell therapy that shows very high efficacy and similar safety compared to the first-line drug Aubagio for multiple sclerosis (MS) and will be the preferred treatment for a wide range of RMS patients.
-
FDA approves first oral new drug for lupus nephritis
Time of Update: 2021-03-12
On January 22, Aurinia Pharmaceuticals announced FDA approval for Lupkynis (voclosporin, voloxysporin) to be listed as a combination immunosuppressive therapy for the treatment of adult active lupus nephritis (LN).
-
Sudden! A pharmaceutical company issued an announcement full of home office
Time of Update: 2021-03-12
the | Kathy burst! Jilin a pharmaceutical company issued an announcement, because the area was adjusted to a high-risk area, all employees at home office pharmaceutical company issued an announcement
-
Jansen EGFR/MET dual-specific antibodies had positive results in the treatment of specific non-small cell lung cancer
Time of Update: 2021-03-12
Janssen, a unit of Johnson and Johnson, has released the latest results for its dual-specific antibody amivantamab, which is used to treat patients with metastasis or inexorable small cell lung cancer (NSCLC) inserted in the treatment of exosome 20 that carries a dermis growth factor (EGFR).
